Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma
| Status: | Completed |
|---|---|
| Conditions: | Lymphoma, Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/30/2018 |
| Start Date: | November 2004 |
| End Date: | April 7, 2011 |
Phase II Trial of Anti-Angiogenic Therapy With RT-PEPC in Patients With Relapsed Mantle Cell Lymphoma
Primary Objective:
Evaluate the clinical activity of the RT-PEPC combination regimen (rituximab, thalidomide,
and prednisone, etoposide, procarbazine, cyclophosphamide) in patients with relapsed mantle
cell lymphoma. Specifically, response rate (RR) and time to disease progression (TTP) will be
assessed.
Secondary Objectives:
1. Assess the toxicity profiles of RT-PEPC treatment in patients with relapsed mantle cell
lymphoma.
2. Prospectively characterize the angiogenic profile of patients with mantle cell lymphoma
during treatment with RT-PEPC. The dynamics of the angiogenic profile will be correlated
with clinical response to RT-PEPC therapy.
3. Assess the quality of life of patients receiving RT-PEPC treatment
Evaluate the clinical activity of the RT-PEPC combination regimen (rituximab, thalidomide,
and prednisone, etoposide, procarbazine, cyclophosphamide) in patients with relapsed mantle
cell lymphoma. Specifically, response rate (RR) and time to disease progression (TTP) will be
assessed.
Secondary Objectives:
1. Assess the toxicity profiles of RT-PEPC treatment in patients with relapsed mantle cell
lymphoma.
2. Prospectively characterize the angiogenic profile of patients with mantle cell lymphoma
during treatment with RT-PEPC. The dynamics of the angiogenic profile will be correlated
with clinical response to RT-PEPC therapy.
3. Assess the quality of life of patients receiving RT-PEPC treatment
Inclusion Criteria:
- Histologically confirmed diagnosis of mantle cell Non-Hodgkin's Lymphoma with
characteristic immunophenotypic profiles: CD5(+),CD23(-), CD19(+) or CD20(+), cyclin
D1(+), and CD10(-)
- Patient has persistent / recurrent disease after standard chemotherapy
- Patient has not received either standard or investigational drugs within the last 3
weeks
- Available frozen tumor tissue obtained since completion of last prior therapy
(rebiopsy if needed)
- Patient has measurable disease as defined by a tumor mass > 1.5 cm in one dimension
- Age > 18 years
- Absolute granulocyte count > 1000 cells/mm3
- Platelet count > 50,000 cells/mm3
- Creatinine < 2.0 x ULN
- Total bilirubin < 2.0 x ULN
- Patient has KPS > 50%
- Patient agrees to use birth control if of reproductive potential
Exclusion Criteria:
- Known central nervous system (CNS) involvement by lymphoma
- Known HIV disease
- Known peripheral neuropathy > grade 2
- Patient is pregnant or nursing
- Patient has had major surgery within the last 3 weeks
- Patient is receiving other investigational drugs
We found this trial at
1
site
Weill Medical College of Cornell University Founded in 1898, and affiliated with what is now...
Click here to add this to my saved trials
